EN DE
Watch BioAge Labs, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BioAge Labs, Inc (BIOA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of BioAge Labs, Inc stock $4.88, price $5.34, that is 8.6% below the price, quality 31 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

BL BioAge Labs, Inc logo Thin data Nov 8, 2026

BioAge Labs, Inc

BIOA · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value $4.88 · Fairly valued (−8.6%)
Insiders sold $1.6M (6M)
Revenue last quarter 86% below a year ago.
Quality 31/100
Weak Growth
Negative free cash flow
Trails peers (3/8)
Narrow moat 8/100 · thin data
Thin data
⚠ Dilution
Watch BioAge Labs, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$25.83 $3.04 Fair Value $4.88 Sep 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

25‑month range $3.04 – $25.83 · fair‑value band $3.22 – $6.10 · the $5.34 price screens above the $4.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow BioAge Labs in your weekly email

Every Wednesday you see whether BioAge Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Show moreShow less

Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.

The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate.

BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Stock analysis

BioAge Labs, Inc (BIOA) currently trades at $5.34, while our model-based Fair Value estimate is $4.88, so the stock looks roughly fairly valued today (gap 9.4%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $3.22 (bear) to $6.10 (bull), the price of $5.34 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

BioAge Labs, Inc reported revenue of $9.0M in FY2025 versus $14.9M in FY2017, a compound −6.1%/yr. Reported net income was −$80.6M in FY2025.

Key figures

Market cap $239M Micro · P/S ratio 28.5 · EPS (TTM) $−2.56 · Return on equity −34.6% · Return on assets (EBIT) −108% (5-year average) · Operating margin −12,554% · Revenue (TTM) $8.6M · Revenue growth (YoY) −85.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −9%, BIOA screens cheaper than that median.

Fair Value models

Bear $3.22 Fair Value $4.88 Bull $6.10
Price $5.34 · Downside -8.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $3.79 $5.74 $7.18 54
All 1 models by family
Asset-Based
NCAV (Graham) $3.79 $5.74 $7.18 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 24
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $1.6M and none bought.

  • SaleShane BartonPrincipal Accounting Officer62,566 shares at $25.20$1.6MJun 30, 202610b5-1 plan
  • SalePaul D RubinChief Medical Officer6× since Dec 4, 2025: 118,016 shares, avg. $12.38$1.5MApr 1, 202610b5-1 plan
  • SaleDov A Goldstein MdChief Financial Officer27,000 shares at $19.70$531,844Jan 13, 202610b5-1 plan
  • SaleKristen FortneyChief Executive Officer, Director233,107 shares at $18.12$4.2MJan 13, 202610b5-1 plan

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,545.1% (2013) → −1,031.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BIOA, get fair value alerts →

Compare BioAge Labs, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −8.6% · Above median
Profitability
Return on assets −27.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −85.5% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.88× · Cheapest 25%
P/S (12 months) 27.85× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs BIOA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs BIOA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs BIOA
Haleon plc HLN $9.14 $8.61 −6% vs BIOA
Merck KGaA MRK €148.75 €109.18 −27% vs BIOA
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs BIOA
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs BIOA
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs BIOA
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs BIOA
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs BIOA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioAge Labs, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BioAge Labs, Inc Fair Value". https://www.fairvalue-calculator.com/stock/BIOA

Frequently asked questions

Is BioAge Labs, Inc (BIOA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $4.88 versus a price of $5.34, about 9% lower (fairly valued).
What is the fair value of BIOA?
Our model-based fair value for BioAge Labs, Inc is $4.88 (as of Nov 8, 2026), built from audited fundamentals. The current price: $5.34.
What is the quality score of BIOA?
BioAge Labs, Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioAge Labs, Inc (BIOA)?
Our model-based price target is the fair value of $4.88 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $3.22, optimistic scenario $6.10. It is a calculation from audited fundamentals, not an analyst target.
What is the BioAge Labs, Inc stock forecast for 2026?
Our models put fair value at $4.88, about 9% lower versus a price of $5.34 (fairly valued). Cautious scenario $3.22, optimistic scenario $6.10. The calculation is refreshed regularly with new filings.
What is the revenue of BioAge Labs, Inc (BIOA)?
BioAge Labs, Inc reported trailing-twelve-month revenue of about $8.6M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of BioAge Labs, Inc (BIOA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioAge Labs, Inc it is $4.88 per share (as of Nov 8, 2026), against a price of $5.34. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is BioAge Labs, Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, BIOA trades above its calculated fair value: price $5.34, fair value $4.88, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOA?
No. The price is what the market pays today ($5.34); the fair value is what the company's own numbers justify ($4.88). For BioAge Labs, Inc the two are $0.4610 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioAge Labs, Inc worth?
The market values BioAge Labs, Inc at about $239M (market capitalisation, as of Nov 8, 2026). Per share that is $5.34; our models calculate a fair value of $4.88 per share.
What do the bullish and bearish scenarios say about BIOA?
Our models span a range for BioAge Labs, Inc: cautious scenario $3.22, base $4.88, optimistic $6.10 per share (as of Nov 8, 2026, price $5.34). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioAge Labs, Inc (BIOA)?
Balance-sheet figures for BioAge Labs, Inc (as of Nov 8, 2026): return on equity −34.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is BIOA from its 52-week high?
BioAge Labs, Inc trades at $5.34, about 79% below its 52-week high of $25.10 and 10% above the low of $4.84 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $4.88 is for.
Which stocks are comparable to BioAge Labs, Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioAge Labs, Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $5.34, calculated fair value $4.88 (−9%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOA calculated?
We run BioAge Labs, Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $4.88 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. BioAge Labs, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioAge Labs, Inc (BIOA)?
The closing price on Nov 6, 2026 was $5.34. Our model-based fair value is $4.88, about 9% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioAge Labs, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($3.22 to $6.10) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of BioAge Labs, Inc

How large is the market capitalisation of BioAge Labs, Inc (BIOA)?
The market capitalisation of BioAge Labs, Inc is $239M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioAge Labs, Inc (BIOA)?
The price-to-sales ratio of BioAge Labs, Inc is 28.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioAge Labs, Inc (BIOA)?
Earnings per share at BioAge Labs, Inc are $−2.56. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BioAge Labs, Inc (BIOA)?
The return on equity (ROE) of BioAge Labs, Inc is −34.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioAge Labs, Inc (BIOA)?
On an EBIT basis the return on assets of BioAge Labs, Inc is −108% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioAge Labs, Inc (BIOA)?
The operating margin of BioAge Labs, Inc is −12,554% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioAge Labs, Inc (BIOA)?
Revenue at BioAge Labs, Inc is growing −85.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BioAge Labs, Inc (BIOA) generate?
The free cash flow of BioAge Labs, Inc is −$82.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BioAge Labs, Inc (BIOA) hold?
BioAge Labs, Inc holds more cash than debt, $183M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BioAge Labs, Inc in the live analysis

One click puts BioAge Labs, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.